✦ LIBER ✦

Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients

✍ Scribed by Sarah B. Blackman; Timothy L. Lash; Aliza K. Fink; Patricia A. Ganz; Rebecca A. Silliman

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 92 KB
Volume: 95
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.10985

No coin nor oath required. For personal study only.

✦ Synopsis

Background:

Adjuvant tamoxifen is recommended for all women with estrogen receptor-positive breast carcinoma without regard for age. we investigated age-dependent variations in adjuvant tamoxifen prescription patterns in a cohort of women 80 years of age and older.

Methods:

We studied 92 women diagnosed at four u.s. sites with primary, early-stage breast carcinoma. each woman consented to a medical record review and participated in two telephone interviews. we compared the proportion of tamoxifen prescriptions received by women 85-92 years of age with those received by women 80-84 years of age. relative risks (rr) and 95% confidence intervals (95% ci) were generated using generalized estimating equations. confounding by demographic, disease, and treatment characteristics was assessed.

Results:

Before adjustment, patients 85-92 years of age were 28% less likely to receive a tamoxifen prescription compared with patients 80-84 years of age (rr = 0.72, 95% ci 0.57-0.91). in this sample, patients not prescribed tamoxifen had substantially more comorbidity. after adjusting the crude finding for comorbidity, the rr was 0.74 (95% ci 0.58-0.93). in addition, the oldest patients and those not prescribed tamoxifen were significantly less likely to be married or have living children. after adjusting the crude finding for these two factors, the rr was 0.75 (95% ci 0.59-0.95). there was no confounding by the other demographic, disease, or treatment covariates assessed.

Conclusion:

Given the increasing longevity of the oldest old, undertreatment with adjuvant tamoxifen may put older breast carcinoma patients at an increased risk of disease recurrence and breast carcinoma mortality.

📜 SIMILAR VOLUMES

The cost of adjuvant chemotherapy in pat

The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma

✍ Nina Oestreicher; Scott D. Ramsey; Jeannine S. McCune; Hannah M. Linden; David L 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract ## BACKGROUND In the U.S., the majority of premenopausal patients with early‐stage breast carcinoma are treated with adjuvant chemotherapy. However, to the authors' knowledge, there have been few formal analyses of adjuvant chemotherapy cost performed to date, especially in premenopaus

Predicting response to adjuvant and radi

Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma

✍ Harry B. Burke; Albert Hoang; J. Dirk Iglehart; Jeffrey R. Marks 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

## Background: Screening and surveillance is increasing the detection of early stage breast carcinoma. the ability to predict accurately the response to adjuvant therapy (chemotherapy or tamoxifen therapy) or postlumpectomy radiation therapy in these patients can be vital to their survival, because

Excellent outcomes with adjuvant toremif

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer

✍ Jaime D. Lewis; Anees B. Chagpar; Elizabeth A. Shaughnessy; Jacob Nurko; Kelly M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract ## BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. We hypothesized that toremifene as compared with tamoxifen given as adjuvant therapy for early stage breast cancer wo

Twelve-year mortality results of a rando

Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01)

✍ Carol Alliot 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB 👁 1 views

Twelve-year mortality results of a rando

Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01)

✍ Maurizio Belfiglio; Miriam Valentini; Fabio Pellegrini; Giorgia De Berardis; Mon 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND This study evaluated the impact on overall survival (OS) of 2 versus 5 years adjuvant tamoxifen in early breast carcinoma patients after 12 years of follow‐up. ## METHODS Women with breast carcinoma T1–3, N0–3, M0, aged 50–70 years, were eligible for this multicenter ra

A randomized trial of long term adjuvant

A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery

✍ Kristina Dalberg; Hemming Johansson; Ulla Johansson; Lars E. Rutqvist 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

## BACKGROUND. The use of adjuvant tamoxifen to treat postmenopausal breast carcinoma patients as an adjunct to primary surgery is well established. The current study reports the long term results for a low risk stratum in a randomized trial of adjuvant tamoxifen. The main focus of this analysis w